2020 Annual Report and 2021 AGM Notice

RNS Number : 5555D

Open Orphan PLC

30 June 2021

 

Open Orphan plc

("Open Orphan", the "Company")

2020 Annual Report and 2021 AGM Notice

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , announces that the following documents have been sent to shareholders:

· Annual Report and Accounts for the year ended 31 December 2020 ("2020 Annual Report")

· Notice of Annual General Meeting ("AGM") 2021 and voting proxy form

In accordance with AIM Rule 26, these documents are also available to view on the Company's website:

https://www.openorphan.com/investors/reports-and-presentations/year/2021 .

The 2020 Annual Report, and the Notice of AGM, which includes details of voting by proxy, have been posted to shareholders who have not consented to receive electronic communications.

The AGM is scheduled to be held at 12 noon BST on 21 July 2021 at the offices of Arden Partners plc, 125 Old Broad St, London EC2N 1AR, and will consider the resolutions set out in the Notice of AGM.

In light of the UK Government's response to the ongoing COVID-19 outbreak, the Company and the Executive Chairman have determined that the Resolutions to be proposed at the AGM shall be voted on through a poll rather than on a show of hands; and, accordingly, shareholders are strongly encouraged to either submit their Form of Proxy or use the CREST Proxy Voting Service, rather than attend the meeting in person.

Interested in becoming a volunteer?

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website,  www.flucamp.com . By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.

If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at  www.UKCovidChallenge.com .

For further information, please contact:

Open Orphan plc			www.openorphan.com
Cathal Friel, Executive Chairman			[phone]
Arden Partners plc (Nominated Adviser and Joint Broker)			[phone]
John Llewellyn-Lloyd / Richard Johnson / Oscair McGrath
finnCap plc (Joint Broker)			[phone]
Geoff Nash / James Thompson/ Richard Chambers
Davy (Euronext Growth Adviser and Joint Broker)			[phone]
Anthony Farrell
Walbrook PR (Financial PR & IR)		[phone] or [e-mail]
Paul McManus / Sam Allen / Lianne Cawthorne		[phone] / [phone] / [phone]

Notes to Editors

Open Orphan plc  (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.

Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic which also has a highly specialised virology and immunology laboratory on-site. Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD. In addition, Open Orphan is also developing the world's first COVID-19 human challenge study model as part of the  Human Challenge Programme  and has signed a reservation contract with the UK Government for the first three COVID-19 vaccine challenge studies.

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion® platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases.

Open Orphan's Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company's Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial  contracts .

 

END

 

 

ACSSELFAUEFSEEM